In last trading session, Lucid Diagnostics Inc (NASDAQ:LUCD) saw 0.82 million shares changing hands with its beta currently measuring 1.24. Company’s recent per share price level of $1.26 trading at $0.03 or 2.44% at ring of the bell on the day assigns it a market valuation of $136.32M. That closing price of LUCD’s stock is at a discount of -42.86% from its 52-week high price of $1.80 and is indicating a premium of 46.03% from its 52-week low price of $0.68. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.91 million shares which gives us an average trading volume of 1.07 million if we extend that period to 3-months.
For Lucid Diagnostics Inc (LUCD), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Lucid Diagnostics Inc (NASDAQ:LUCD) trade information
Upright in the green during last session for gaining 2.44%, in the last five days LUCD remained trading in the green while hitting it’s week-highest on Friday, 05/16/25 when the stock touched $1.26 price level, adding 2.33% to its value on the day. Lucid Diagnostics Inc’s shares saw a change of 53.90% in year-to-date performance and have moved 11.50% in past 5-day. Lucid Diagnostics Inc (NASDAQ:LUCD) showed a performance of 15.60% in past 30-days. Number of shares sold short was 1.34 million shares which calculate 0.93 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 2 to the stock, which implies a rise of 37.0% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 2. It follows that stock’s current price would drop -58.73% in reaching the projected high whereas dropping to the targeted low would mean a loss of -58.73% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -54.43% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 38.99% while estimates for its earnings growth in next 5 years are of 37.27%.
Lucid Diagnostics Inc (NASDAQ:LUCD)’s Major holders
Insiders are in possession of 34.22% of company’s total shares while institution are holding 9.78 percent of that, with stock having share float percentage of 14.86%. Investors also watch the number of corporate investors in a company very closely, which is 9.78% institutions for Lucid Diagnostics Inc that are currently holding shares of the company. LUMINUS MANAGEMENT LLC is the top institutional holder at LUCD for having 0.73 million shares of worth $0.6 million. And as of 2024-06-30, it was holding 1.6124 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 0.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.2461 of outstanding shares, having a total worth of $0.46 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 366.92 shares of worth $0.46 million or 0.34% of the total outstanding shares. The later fund manager was in possession of 193.99 shares on Dec 31, 2024 , making its stake of worth around $0.24 million in the company or a holder of 0.18% of company’s stock.
